Nuvo Research Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario as Clark Pharmaceutical Laboratories Ltd. On November 14, 1990, the articles were amended to change the name of the Company from Clark Pharmaceutical Laboratories Ltd. to Dimethaid Research Inc. On September 30, 2005, the articles were further amended to change the name of the Company from Dimethaid Research Inc. to Nuvo Research Inc. On January 1, 2007, the Company completed a short-form amalgamation with Akorn Pharmaceuticals Canada Limited, Excelpharm Inc., Femina Inc., Dimethaid Management Inc. and Dimethaid Manufacturing Inc. The amalgamated entity continues as Nuvo Research Inc.

Nuvo Research Inc. has two Canadian locations. Its registered office and principal place of business is its head office located in Mississauga, Ontario. It also operates a manufacturing facility, Nuvo Manufacturing/Fabrication Nuvo, in Varennes, Quebec where it currently manufactures Pennsaid^®.

Dimethaid AG, Dimethaid GmbH and Nuvo Research GmbH

In May 2002, the Company completed the acquisition from Dr. F.W. Kühne of Oxo Chemie. Oxo Chemie was a Swiss company headquartered in Fribourg, Switzerland that owned the intellectual property rights relating to WF10. The assets acquired by Nuvo included a OXO-K993 manufacturing plant, equipment and inventory in Wanzleben, Germany and the marketing rights for WF10 in Thailand. OXO-K993, a stabilized chlorite ion solution is used to produce WF10 and Oxoferin^™.

Upon completing the acquisition of Oxo Chemie, it was restructured into Dimethaid AG, Dimethaid GmbH and Dimethaid (Thailand) Limited. Dimethaid AG retained all rights to the WF10 patents and intellectual property. Dimethaid GmbH was incorporated as a new, wholly owned German subsidiary of the Company overseeing the OXO-K993 manufacturing facilities in Wanzleben. Dimethaid (Thailand) Limited was registered in Thailand as a wholly owned subsidiary of Nuvo, with the intent of exploiting WF10 marketing rights in that country.

In November 2004, the Company restructured its relationship with Dr. Kühne and entered into an agreement effective May 31, 2005, to reflect these restructured arrangements. Pursuant to this new agreement, the Company transferred all shares of Dimethaid GmbH to Dimethaid AG, making Dimethaid GmbH a wholly owned subsidiary of Dimethaid AG. Dimethaid (Thailand) Limited, which never commenced operations, transferred its WF10 marketing rights for Thailand to Dr. Kühne and the Company transferred a 40% ownership interest in Dimethaid AG to Dr.Kühne. In 2007, Dimethaid (Thailand) Limited was dissolved.

In July 2008, Dimethaid AG established a wholly owned subsidiary Nuvo Research GmbH (NRG). NRG's office and operations are located in Leipzig, Germany. It will conduct and co-ordinate certain future research and development activities related to WF10 including arranging the necessary funding to conduct such research and development.

fqubed, Inc.

In December 2005, the Company acquired all of the common shares of fqubed, Inc. (fqubed), a company based in San Diego, California. Initially using technology licensed from the University of California, fqubed has developed proprietary screening capabilities to identify innovative formulations that can efficiently deliver active therapeutics into and through the skin. Nuvo is using this technology to expand its pipeline of topically and transdermally delivered therapeutics.

Dimethaid (UK) Limited

Dimethaid (UK) Limited is a British company, incorporated in 1999, that holds the marketing authorization for Pennsaid^® in the United Kingdom.

Dimethaid Immunology Inc.

In June 1993, Dimethaid Immunology Inc. was incorporated as a wholly owned subsidiary of the Company. It was responsible for the Canadian marketing and distribution of WF10, an aqueous solution of Oxo-K993 containing stabilized chlorite ions, as well as related products developed by Oxo Chemie AG of Switzerland ("Oxo Chemie"). Oxo Chemie (now Dimethaid AG) was purchased by the Company in May 2002. Dimethaid Immunology Inc. currently has limited activity since WF10 and related products are not currently approved for sale in Canada.